Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Globus Medical (GMED – Research Report) and ...

Globus Medical GMED has entered into a definitive agreement to acquire Nevro Corp. NVRO in an all-cash transaction valued at approximately $250 million. Under the terms of the agreement, unanimously ...

In a report released today, Matt Miksic from Barclays maintained a Buy rating on Globus Medical (GMED – Research Report), with a price target ...

Jefferies analyst Matthew Taylor revised the stock rating for Nevro Corp (NYSE:NVRO), elevating it from Underperform to Hold. Accompanying this upgrade, the price target also saw an increase to $5.85, ...

Globus Medical (NYSE:GMED) announced today that it agreed to acquire chronic pain treatment developer Nevro (NYSE:NVRO).

Globus Medical, Inc.’s GMED growth in the third quarter can be attributed to the robust prospect in the musculoskeletal space. The company’s merger with NuVasive is expected to generate ...

you should consider Globus Medical (GMED). This company, which is in the Zacks Medical - Instruments industry, shows potential for another earnings beat. This medical device company has seen a ...

Stock analysts at Roth Capital dropped their FY2024 earnings per share (EPS) estimates for shares of Globus Medical in a ...

Globus Medical (NYSE:GMED) said it has agreed to buy Nevro (NVRO) through an all-cash deal with an equity value of around $250M. Under the deal, Globus Medical (NYSE:GMED) will buy all of Nevro's ...

周一，Jefferies分析师Matthew Taylor调整了Nevro Corp (NYSE: NVRO )的股票评级，从"减持"上调至"持有"。同时，目标价也从此前的$4.50上调至$5.85。这一调整是在Nevro最近宣布被GMED收购后做出的，Taylor对GMED持积极态度。目前，Nevro股价报$5.72，过去一周强劲上涨14.86%。根据 InvestingPro ...

The company currently has its sales operations distributed across 51 counties worldwide. GMED is a Zacks Rank #3 (Hold) stock, with a Growth Style Score of A and VGM Score of A. Earnings are expected ...